Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- M00896 - Provider product page
- Provider
- Boster Biological Technology
- Product name
- Anti-Lin28B Rabbit Monoclonal Antibody
- Antibody type
- Monoclonal
- Description
- Monoclonal antibody for LIN-28B/LIN28B detection. Host: Rabbit.Size: 100ug/vial. Tested applications: Flow Cytometry, IP, IF, ICC, WB. Reactive species: Human LIN-28B/LIN28B information: Molecular Weight: 27084 MW; Subcellular Localization: Nucleus. Nucleus, nucleolus . Cytoplasm . Predominantly nucleolar (PubMed:22118463). In Huh7 cells, predominantly cytoplasmic, with only a subset of cells exhibiting strong nuclear staining; however, the specificity of the polyclonal antibody used in these experiments has not been not documented (PubMed:16971064); Tissue Specificity: Expressed at high levels in the placenta and, at mucher lower, in testis and fetal liver (PubMed:16971064). Isoform 1 is only detected in placenta and in moderately and poorly differentiated hepatocellular carcinoma cells (at protein level). Isoform 2 is detected in fetal liver, non-tumor liver tissues, as well as well-differentiated tumor tissues (at protein level). Tends to be up-regulated in triple-negative (ER-, PR-, HER2-) breast tumors, as well as in liver, ovarian, and thyroid carcinomas (PubMed:22118463).
- Reactivity
- Human
- Host
- Rabbit
- Antibody clone number
- EAA-12
- Vial size
- 100ug/vial
- Concentration
- 0.5-1mg/ml, actual concentration vary by lot. Use suggested dilution ratio to decide dilution procedure.
- Storage
- At -20°C for one year. Avoid repeated freezing and thawing.
Submitted references Anti-inflammatory Effects of Phyllanthus emblica L on Benzopyrene-Induced Precancerous Lung Lesion by Regulating the IL-1β/miR-101/Lin28B Signaling Pathway.
Wang CC, Yuan JR, Wang CF, Yang N, Chen J, Liu D, Song J, Feng L, Tan XB, Jia XB
Integrative cancer therapies 2017 Dec;16(4):505-515
Integrative cancer therapies 2017 Dec;16(4):505-515
No comments: Submit comment
No validations: Submit validation data